OncoCyte (OCX) News Today $3.44 +0.05 (+1.47%) Closing price 04:00 PM EasternExtended Trading$3.44 +0.00 (+0.12%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period OncoCyte (NASDAQ:OCX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a research note on Tuesday.April 10, 2025 | marketbeat.comStockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)StockNews.com started coverage on OncoCyte in a report on Sunday. They issued a "sell" rating for the company.April 8, 2025 | marketbeat.comOncoCyte Co. (NASDAQ:OCX) Sees Large Growth in Short InterestOncoCyte Co. (NASDAQ:OCX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 373,800 shares, an increase of 22.4% from the February 28th total of 305,500 shares. Approximately 2.5% of the company's stock are sold short. Based on an average daily volume of 89,700 shares, the short-interest ratio is currently 4.2 days.April 4, 2025 | marketbeat.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comStockNews.com started coverage on shares of OncoCyte in a research note on Monday. They set a "sell" rating on the stock.April 1, 2025 | marketbeat.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Pura Vida Investments LLCPura Vida Investments LLC boosted its stake in OncoCyte Co. (NASDAQ:OCX - Free Report) by 32.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 654,451 shares of the company's stock afterMarch 31, 2025 | marketbeat.comOncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at Lake Street CapitalLake Street Capital began coverage on shares of OncoCyte in a research note on Friday. They issued a "buy" rating and a $5.00 price objective for the company.March 29, 2025 | marketbeat.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comOncoCyte's (OCX) Equal Weight Rating Reiterated at StephensStephens restated an "equal weight" rating and issued a $4.00 target price on shares of OncoCyte in a research note on Tuesday.March 26, 2025 | marketbeat.comOncoCyte's (OCX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $4.25 target price on shares of OncoCyte in a research note on Tuesday.March 26, 2025 | marketbeat.comOncocyte Corp. Reports Q4 2024 Results with $1.5 Million in Revenue and Significant Clinical Advancements in Transplant TestingMarch 26, 2025 | nasdaq.comOncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comOncoCyte (NASDAQ:OCX) Announces Earnings ResultsOncoCyte (NASDAQ:OCX - Get Free Report) announced its earnings results on Monday. The company reported $0.48 earnings per share for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%.March 25, 2025 | marketbeat.comOncocyte targets $20M in recurring revenue from 20 transplant centers by 2025March 24, 2025 | msn.comOncoCyte Corporation (OCX) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comOncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsMarch 24, 2025 | globenewswire.comOncoCyte Corporation (OCX): Among Top Insider Purchases Last MonthMarch 14, 2025 | msn.comOncoCyte (NASDAQ:OCX) Trading Up 14.7% - Should You Buy?OncoCyte (NASDAQ:OCX) Trading Up 14.7% - Here's WhyMarch 5, 2025 | marketbeat.comOncoCyte Corporation (OCX): Among Penny Stocks with Insider Buying in 2025March 4, 2025 | msn.comOncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.comOncocyte corp CFO buys $200,000 in stockFebruary 12, 2025 | msn.comAndrea S. James Buys 97,561 Shares of OncoCyte Co. (NASDAQ:OCX) StockFebruary 12, 2025 | insidertrades.comOncocyte corp's Patrick Smith acquires shares worth $2.2 millionFebruary 11, 2025 | msn.comBroadwood Partners acquires OncoCyte shares worth $9.24 millionFebruary 11, 2025 | msn.comOncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 11, 2025 | globenewswire.comOncocyte Prices $29.1 Million Equity OfferingFebruary 10, 2025 | globenewswire.comOncocyte corp investor Patrick Smith buys $1,839 in sharesFebruary 5, 2025 | msn.comInsider Stock Buying Reaches US$508.4k On OncoCyteJanuary 31, 2025 | finance.yahoo.comOncoCyte stock hits 52-week low at $1.92 amid market challengesJanuary 22, 2025 | msn.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 5,669 Shares of StockJanuary 16, 2025 | insidertrades.comOncoCyte appoints Billings as consulting CMOJanuary 8, 2025 | markets.businessinsider.comOncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerJanuary 8, 2025 | globenewswire.comOncocyte Expands Market Opportunity for VitaGraft™ KidneyJanuary 6, 2025 | globenewswire.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 90,219 Shares of StockDecember 31, 2024 | insidertrades.comAndrew Arno Purchases 12,500 Shares of OncoCyte Co. (NASDAQ:OCX) StockDecember 27, 2024 | insidertrades.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) CFO Purchases 20,000 Shares of StockDecember 10, 2024 | insidertrades.comOncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsDecember 9, 2024 | globenewswire.comOncoCyte Corporation: Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyDecember 5, 2024 | finanznachrichten.deOncoCyte announces publication of DetermaCNI assay dataDecember 4, 2024 | markets.businessinsider.comOncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyDecember 4, 2024 | globenewswire.comOncoCyte announces VitaGraft data published in journalDecember 4, 2024 | markets.businessinsider.comOncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study AffirmsDecember 2, 2024 | globenewswire.comOncoCyte Corp Reports Q3 2024 Earnings and Strategic UpdatesNovember 13, 2024 | markets.businessinsider.comOncoCyte’s Strategic Advances and Financial Prudence Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comOncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...November 13, 2024 | uk.finance.yahoo.comOncoCyte Corporation (OCX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.com Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Media Mentions By Week OCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼0.500.74▲Average Medical News Sentiment OCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼11▲OCX Articles Average Week Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phathom Pharmaceuticals News REGENXBIO News Benitec Biopharma News Allogene Therapeutics News Oruka Therapeutics News Alpha Teknova News Entrada Therapeutics News Mereo BioPharma Group News Heron Therapeutics News Cryoport News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCX Stock Free OCX Stock Alerts